We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This document explains the Prostate Cancer Risk Management Programme (PCRMP), PSA testing and evidence against a national screening programme.
This prostate cancer risk management programme (PCRMP) information is to help GPs advise men aged 50 and over who ask about prostate specific antigen (PSA) testing.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
The trial will use innovative screening methods like an MRI scan and see hundreds of thousands of men across the country participating.
This information aims to support GPs to give clear and balanced advice to men without symptoms of prostate disease who ask about PSA testing.
These documents describe the NHS prostate cancer risk management programme (PCRMP) and its associated prostate specific antigen (PSA) test.
A statement from the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC).
NHS prostate cancer risk management programme (PCRMP) guidance on performing an ultrasound-guided prostate biopsy.
This document contains a synopsis of causation occurring in cancer of the prostate.
The Advisory Committee on Releases to the Environment's advice on an application for a trial of a genetically modified cancer vaccine.
Six new NHS trusts across England will receive funding for groundbreaking trial of artificial intelligence (AI) to diagnose prostate cancer quicker.
How to use a patient-reported outcomes and experiences study to evaluate your digital health product.
Cancer diagnoses and age-standardised incidence rates for all types of cancer by age, sex and region including breast, prostate, lung and colorectal cancer.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.